Herbal COVID-19 treatment trial pulled before it began
NCT ID NCT05552625
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study planned to test TADIOS, a blend of three herbs used in traditional Asian medicine, as an add-on treatment for adults hospitalized with mild to moderate COVID-19. Participants would have received TADIOS or a placebo for up to 10 days. The goal was to see if TADIOS could improve recovery and reduce inflammation. However, the trial was withdrawn before enrolling anyone, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TADIOS (a combination of three herbs traditionally used for respiratory issues in Asia)
- What this could lead to
- If it had worked, TADIOS might have helped reduce inflammation and speed recovery from mild to moderate COVID-19.
- What could go wrong
- The trial was withdrawn before any participants were enrolled, so no data on safety or effectiveness exist. Herbal supplements can vary in quality and may interact with other medications.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2/3
Runs two stages together: whether the treatment works, then large-scale confirmation.
- Expected to start
-
May 2021
An estimate. Start dates often move.
- Expected to finish
-
Feb 2022
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Male or Female, aged between 18 to 65 years (both inclusive) 2. Confirmed Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) first infection by a reverse transcription polymerase chain reaction (RT-PCR) assay in nasal swab or oropharyngeal swab samples. 3. Patients who are hospitalized into designated hospital for COVID-19 treatment 4. Patients who can be treated within 24 hours after confirmed diagnosis with COVID-19 5. Patients with mild COVID-19 or moderate COVID-19 according to clinical management guideline of Government of India. * Mild Illness: Patients with uncomplicated upper respiratory tract viral infection, may have non-specific symptoms such as fever, cough, sore throat, nasal congestion, malaise, and headache. The elderly may present with atypical symptoms. These patients do not have any signs of dehydration, sepsis or shortness of breath. * Moderate Illness: Patient with pneumonia and no signs of severe pneumonia (Chest X-ray will be performed to rule out pneumonia in the suspected subjects). 6. Patients who have signed the written informed consent form approved by Ethics Committee to participate after understanding explanations regarding the study 7. Those who can comply with the requirements and processes in the clinical study 8. Women of childbearing age must be negative to urine pregnancy test during screening Exclusion Criteria: 1. Patients with severe COVID-19 2. Self-reported history of meaningful circulatory, renal, gastrointestinal, liver, endocrinal, hematological, or mental disease, or other serious diseases or alcohol or drug addiction that may cause safety issues or confusion in the interpretation of clinical research results by the principal investigator's judgment 3. Female patients who are pregnant (confirmed through urine pregnancy test) or breastfeeding 4. Patients with cardiovascular, liver, cancer and kidney disease. 5. Self-reported patients being a recipient of immunosuppressive therapy 6. Self-reported patients who are allergic to this dietary supplements 7. Patients taking a health functional food or medicine that may affect the body's antioxidant, anti-inflammatory activity, and lungs within 6 weeks of the first visit 8. Patients who participated in another clinical trial within 1 month before screening 9. Patients have any condition that in the judgement of investigator make the subject inappropriate for entry into this study 10. Patients consuming any herbal medicine 11. Self-reported patients with cases of surgical menopause (hysterectomy, oophorectomy of both ovaries) or sterilization procedures (tubal ligation or tubectomy of both fallopian tubes). Menopause refers to 1 year of no menstruation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID -19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chaitanya Hospital
Paravūr, Kerala, 683513, India
-
Gunjkar Multispeciality Hospital
Pune, Maharashtra, 4110019, India
-
Lakshmi Nursing Home
Kochi, Kerala, 683101, India
-
Oxycare Multispecialty Hospital
Pune, Maharashtra, 411033, India
-
Sparsh Superspeciality Hospital
Bangalore, Karnataka, 560022, India
-
Vagus Super Specialty Hospital
Bangalore, Karnataka, 560003, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Home antibody tests put to the test: can you read your own COVID-19 result?
- Can lung ultrasound reveal COVID-19's signature in the lungs?
- When the immune system Can't fight back: tracking three respiratory viruses
- The household maze: how does COVID-19 move between family members?
- Can an oral drug stop COVID-19 from turning deadly?
- Can COVID-19 rapid tests slip into HIV and TB clinics without disrupting care?